氯吡格雷：一种针对适应症特异性的药物遗传学的案例。
Clopidogrel: a case for indication-specific pharmacogenetics.
机构信息
College of Pharmacy and Center for Pharmacogenomics, University of Florida, Gainesville, FL, USA.
出版信息
Clin Pharmacol Ther. 2012 May;91(5):774-6. doi: 10.1038/clpt.2012.21.
Abstract
The CYP2C19*2 loss-of-function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta-analyses have supported or discounted the impact of genotype on adverse cardiovascular outcomes during clopidogrel therapy, depending on studies included in the analysis. Here we review these data and conclude that evidence supports a differential effect of genotype on protection from major adverse cardiovascular outcomes following percutaneous coronary intervention (PCI), but not for other clopidogrel indications.
摘要
CYP2C19*2 失活等位基因与氯吡格雷活性代谢物生成减少有关。然而，荟萃分析支持或否定了基因型对氯吡格雷治疗期间不良心血管结局的影响，具体取决于分析中纳入的研究。在此，我们对这些数据进行了回顾，得出的结论是，有证据表明基因型对经皮冠状动脉介入治疗（PCI）后主要不良心血管结局的保护作用存在差异，但对氯吡格雷的其他适应证则没有。
相似文献
1
Clopidogrel: a case for indication-specific pharmacogenetics.
Clin Pharmacol Ther. 2012 May;91(5):774-6. doi: 10.1038/clpt.2012.21.
2
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
JAMA. 2010 Oct 27;304(16):1821-30. doi: 10.1001/jama.2010.1543.
3
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
Clin Pharmacol Ther. 2011 Aug;90(2):328-32. doi: 10.1038/clpt.2011.132. Epub 2011 Jun 29.
4
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Lancet. 2010 Oct 16;376(9749):1312-9. doi: 10.1016/S0140-6736(10)61273-1.
5
Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle.
JAMA. 2010 Oct 27;304(16):1839-40. doi: 10.1001/jama.2010.1566.
6
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.
JAMA. 2011 Dec 28;306(24):2704-14. doi: 10.1001/jama.2011.1880.
7
Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.
Clin Pharmacol Ther. 2011 Mar;89(3):455-9. doi: 10.1038/clpt.2010.316. Epub 2011 Jan 26.
8
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
JAMA. 2009 Aug 26;302(8):849-57. doi: 10.1001/jama.2009.1232.
9
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.
10
Carriage of reduced-function CYP2C19 allele among patients treated with clopidogrel.
JAMA. 2011 Feb 2;305(5):467-8; author reply 468. doi: 10.1001/jama.2011.77.
引用本文的文献
1
Relationship between CYP2C19 Polymorphism and Clopidogrel Resistance in Patients with Coronary Heart Disease and Ischemic Stroke in China.
Genet Res (Camb). 2022 Oct 21;2022:1901256. doi: 10.1155/2022/1901256. eCollection 2022.
2
Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.
J Am Heart Assoc. 2022 Feb 15;11(4):e024159. doi: 10.1161/JAHA.121.024159. Epub 2022 Feb 12.
3
Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel- Example.
Pharmgenomics Pers Med. 2021 May 18;14:569-577. doi: 10.2147/PGPM.S224894. eCollection 2021.
4
Pharmacogenomics for Primary Care: An Overview.
Genes (Basel). 2020 Nov 12;11(11):1337. doi: 10.3390/genes11111337.
5
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Clin Pharmacol Ther. 2021 Mar;109(3):705-715. doi: 10.1002/cpt.2039. Epub 2020 Oct 2.
6
The Effect of CYP2C19 and Nongenetic Factors on Clopidogrel Responsiveness in the MENA Region: A Systematic Review.
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619875520. doi: 10.1177/1076029619875520.
7
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):203-210. doi: 10.1093/ehjcvp/pvz045.
8
Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population.
Pharmgenomics Pers Med. 2018 Jun 8;11:95-106. doi: 10.2147/PGPM.S165805. eCollection 2018.
9
Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.
Circ Res. 2018 Apr 27;122(9):1176-1190. doi: 10.1161/CIRCRESAHA.117.310965.
10
A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.
BMC Res Notes. 2018 Jan 18;11(1):46. doi: 10.1186/s13104-018-3132-0.
本文引用的文献
1
Pharmacogenomics and clopidogrel: irrational exuberance?
JAMA. 2011 Dec 28;306(24):2727-8. doi: 10.1001/jama.2011.1865.
2
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.
JAMA. 2011 Dec 28;306(24):2704-14. doi: 10.1001/jama.2011.1880.
3
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.
BMJ. 2011 Aug 4;343:d4588. doi: 10.1136/bmj.d4588.
4
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
Clin Pharmacol Ther. 2011 Aug;90(2):328-32. doi: 10.1038/clpt.2011.132. Epub 2011 Jun 29.
5
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
N Engl J Med. 2010 Oct 28;363(18):1704-14. doi: 10.1056/NEJMoa1008410. Epub 2010 Aug 29.
6
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
JAMA. 2010 Oct 27;304(16):1821-30. doi: 10.1001/jama.2010.1543.
7
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.
J Am Coll Cardiol. 2010 Jul 6;56(2):134-43. doi: 10.1016/j.jacc.2009.12.071.
8
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
JAMA. 2009 Aug 26;302(8):849-57. doi: 10.1001/jama.2009.1232.
9
Cytochrome p-450 polymorphisms and response to clopidogrel.
N Engl J Med. 2009 Jan 22;360(4):354-62. doi: 10.1056/NEJMoa0809171. Epub 2008 Dec 22.
10
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.
Blood. 2006 Oct 1;108(7):2244-7. doi: 10.1182/blood-2006-04-013052. Epub 2006 Jun 13.
Zotero 插件